((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯 | 173340-23-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: ((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯
• 英文名称: tert-butyl ((1-benzylpiperidin-4-yl)methyl)carbamate
• 英文别名: tert-butyl (1-benzylpiperidin-4-yl)methylcarbamate；tert-butyl N-[(1-benzylpiperidin-4-yl)methyl]carbamate
• CAS: 173340-23-3
• 化学式: C₁₈H₂₈N₂O₂
• mdl: MFCD04123925
• 分子量: 304.433
• InChiKey: SOXSDIKJHXTJEP-UHFFFAOYSA-N

物化性质

• 沸点：
  415.5±18.0 °C(Predicted)
• 密度：
  1.043±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.611
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

SDS

Name:	tert-Butyl n-[(1-benzyl-4-piperidinyl)methyl]carbamate Material Safety Data Sheet
Synonym:	None Known
CAS:	173340-23-3

Section 1 - Chemical Product MSDS Name:tert-Butyl n-[(1-benzyl-4-piperidinyl)methyl]carbamate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
173340-23-3	tert-Butyl n-[(1-benzyl-4-piperidinyl)	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 20/21/22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Harmful if absorbed through the skin. Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Harmful if inhaled. Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 173340-23-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 100 - 101 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C18H28N2O2
Molecular Weight: 304.44

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Acid chlorides, reducing agents, strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 173340-23-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl n-[(1-benzyl-4-piperidinyl)methyl]carbamate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8
UN Number: 2923
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8
UN Number: 2923
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8
UN Number: 2923
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 173340-23-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 173340-23-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 173340-23-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  ((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-苄基哌啶-4-甲胺
  参考文献：
  名称：

  发现新型 N-(蒽-9-基甲基) 苯甲酰胺衍生物作为 ZNF207 抑制剂，有望治疗胶质瘤

  摘要：

  针对肿瘤干性是一种创新的癌症治疗方法。锌指蛋白 207 (ZNF207) 是削弱神经胶质瘤细胞干性的一个有前景的靶点。在此，合理设计并合成了一系列针对ZNF207的新型N- (蒽-9-基甲基)苯甲酰胺衍生物。评估了抑制活性，并总结了它们的构效关系。其中， C16表现出最有效的抑制活性，其抑制球体形成的 IC 50值范围为 0.5-2.5 μM，抑制细胞毒性的 IC 50 值范围为 0.5-15 μM。此外，我们发现C16在体外可以阻碍肿瘤的发生和迁移并促进细胞凋亡。这些影响归因于干相关基因的下调。体内评估表明， C16表现出有效的血脑屏障渗透性，并且在皮下和原位神经胶质瘤模型中具有强大的功效。因此， C16可能作为靶向 ZNF207 的潜在先导化合物，对神经胶质瘤具有良好的治疗潜力。

  DOI：

  10.1021/acs.jmedchem.3c02241
• 作为产物：
  描述：

  哌啶-4-甲酰胺 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 ((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯
  参考文献：
  名称：

  N-炔丙基哌啶与萘-2-甲酰胺或萘-2-磺酰胺部分：潜在的多功能抗阿尔茨海默氏病药物

  摘要：

  在阿尔茨海默氏病患者的大脑中，丁酰胆碱酯酶（BChE）和单胺氧化酶B（MAO-B）的酶活性增加。虽然BChE是减轻胆碱能功能减退引起的症状的可行治疗靶标，但MAO-B是预防阿尔茨海默氏病神经退行性变的潜在治疗靶标。从基于哌啶的选择性人（h）BChE抑制剂和基于炔丙基胺的MAO抑制剂开始，我们已经设计，合成和生化评估了一系列N-炔丙基哌啶。所有这些化合物对hBChE的抑制作用均优于相关酶，乙酰胆碱酯酶，并在平行的人工膜渗透测定中越过血脑屏障。一种抑制剂（化合物的晶体结构）3）与hBChE复合显示其结合模式。三种化合物（4，5，6）表明MAO-B的伴随抑制。另外，最有效的hBChE抑制剂7和双重BChE和MAO-B抑制剂6是无细胞毒性的，并且受毒性淀粉样β肽物质保护的神经元SH-SY5Y细胞。

  DOI：

  10.1016/j.bmc.2016.11.032
• 作为试剂：
  描述：

  1-苄基哌啶-4-甲胺 、 二碳酸二叔丁酯 、 potassium carbonate 在 乙酸乙酯 、 水 、 Sodium sulfate-III 、 ((1-苄基哌啶-4-基)甲基)氨基甲酸叔丁酯 作用下， 以 dioxane-water 为溶剂， 以afforded 8.3 g of the intermediate 1-benzyl-piperidin-4-ylmethyl-carbamic acid t-butyl ester as a clear oil的产率得到4-Boc-氨甲基哌啶
  参考文献：
  名称：

  Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists

  摘要：

  该发明提供了公式I的化合物，其结构如下：1其中A，B，Z，R和R1如前所定义，或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢性疾病（通常与肥胖或葡萄糖不耐症有关），动脉硬化，胃肠道疾病，神经遗传性炎症，青光眼，眼压增高和频繁排尿; 特别适用于治疗或抑制2型糖尿病。

  公开号：

  US20020037907A1

文献信息

• Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
  申请人：Bosch Michael

  公开号：US20080269170A1

  公开（公告）日：2008-10-30

  The disclosure relates to compounds of formula (I): wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.

  该披露涉及到式(I)的化合物：其中R1-R5、A和Y如披露中所定义，以及包含该化合物的组合物，以及制备该化合物的方法和使用该化合物的方法。
• Discovery and Biological Evaluation of <i>N</i>-Methyl-pyrrolo[2,3-<i>b</i>]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors
  作者：Eunsun Park、Sun Joo Lee、Heegyum Moon、Jongmi Park、Hyeonho Jeon、Ji Sun Hwang、Hayoung Hwang、Ki Bum Hong、Seung-Hee Han、Sun Choi、Soosung Kang

  DOI：10.1021/acs.jmedchem.0c01026

  日期：2021.1.28

  binding modes of current JAK inhibitors to JAK isoforms allowed the design of N-alkyl-substituted 1-H-pyrrolo[2,3-b] pyridine carboxamide as a JAK1-selective scaffold, and the synthesis of various methyl amide derivatives provided 4-((cis-1-(4-chlorobenzyl)-2-methylpiperidin-4-yl)amino)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (31g) as a potent JAK1-selective inhibitor. In particular, the (S,S)-enantiomer

  Janus激酶1（JAK1）在大多数细胞因子介导的通过JAK / STAT信号传导的炎症和自身免疫反应中起关键作用；因此，抑制JAK1是对几种疾病的有前途的治疗策略。分析目前的JAK抑制剂与JAK同工型的结合方式，可以设计N-烷基取代的1- H-吡咯并[2,3- b ]吡啶羧酰胺作为JAK1选择性骨架，并合成各种甲基酰胺衍生物提供了4-（（顺式-1-（4-氯苄基）-2-甲基哌啶-4-基）氨基）-N-甲基-1H-吡咯并[2,3 - b ]吡啶-5-甲酰胺（31g），一种有效的JAK1选择性抑制剂。特别是（31 g（38a）的S，S） -对映异构体对JAK1表现出出色的效力，并具有超过JAK2，JAK3和TYK2的选择性。在研究31g对肝纤维化的作用时，发现它降低了TGF-β诱导的肝星状细胞（HSCs）的增殖和纤维生成基因表达。具体而言，在伤口愈合试验中，31g显着抑制TGF-β诱导的0.25μMHSC迁移。
• Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists
  作者：I. Adlere、S. Sun、A. Zarca、L. Roumen、M. Gozelle、C. Perpiñá Viciano、B. Caspar、M. Arimont、J.P. Bebelman、S.J. Briddon、C. Hoffmann、S.J. Hill、M.J. Smit、H.F. Vischer、M. Wijtmans、C. de Graaf、I.J.P. de Esch、R. Leurs

  DOI：10.1016/j.ejmech.2018.10.060

  日期：2019.1

  Using the available structural information of the chemokine receptor CXCR4, we present hit finding and hit exploration studies that make use of virtual fragment screening, design, synthesis and structure-activity relationship (SAR) studies. Fragment 2 was identified as virtual screening hit and used as a starting point for the exploration of 31 N-substituted piperidin-4-yl-methanamine derivatives to

  利用趋化因子受体CXCR4的可用结构信息，我们提出了利用虚拟片段筛选，设计，合成和结构-活性关系（SAR）研究的命中发现和命中探索研究。片段2被鉴定为虚拟筛选命中点，并被用作探索31种N-取代的哌啶-4-基-甲胺衍生物的起点，以研究和改善与CXCR4结合位点的相互作用。另外，细微的结构配体变化导致与CXCR4发生明显的相互作用，导致CXCL12结合的完全或部分移位以及竞争性和/或非竞争性拮抗作用。三维定量结构-活性关系（3D-QSAR）和结合模型研究用于确定重要的疏水相互作用，这些相互作用决定了结合亲和力并表明了关键的配体-受体相互作用。
• Claulansine F–Donepezil Hybrids as Anti-Alzheimer’s Disease Agents with Cholinergic, Free-Radical Scavenging, and Neuroprotective Activities
  作者：Yingda Zang、Ke Liu、Weiping Wang、Chuangjun Li、Jie Ma、Jingzhi Yang、Xinyi Chen、Xiaoliang Wang、Dongming Zhang

  DOI：10.3390/molecules26051303

  日期：——

  The multifactorial nature of Alzheimer’s disease (AD) calls for the development of multitarget agents addressing key pathogenic processes. A total of 26 Claulansine F–donepezil hybrids were designed and synthesized as multitarget drugs. Among these compounds, six compounds exhibited excellent acetylcholinesterase (AChE) inhibitory activity (half maximal inhibitory concentration (IC50) 1.63–4.62 μM). Moreover, (E)-3-(8-(tert-Butyl)-3,3-dimethyl-3,11-dihydropyrano[3,2-a]carbazol-5-yl)-N-((1-(2-chlorobenzyl)piperidin-4-yl)methyl)acrylamide (6bd) exhibited better neuroprotective effects against OGD/R (oxygen–glucose deprivation/reoxygenation) than lead compound Claulansine F. Furthermore, 6bd could cross the blood–brain barrier in vitro. More importantly, compared to edaravone, 6bd had stronger free-radical scavenging activity. Molecular docking studies revealed that 6bd could interact with the catalytic active site of AChE. All of these outstanding in vitro results indicate 6bd as a leading structure worthy of further investigation.

  阿尔茨海默病（AD）的多因素性质需要开发多靶点药物，以应对关键的病理过程。总共设计和合成了26种Claulansine F-donepezil杂合物作为多靶点药物。在这些化合物中，有六种表现出优秀的乙酰胆碱酯酶（AChE）抑制活性（半最大抑制浓度（IC50）为1.63-4.62μM）。此外，（E）-3-（8-（叔丁基）-3,3-二甲基-3,11-二氢吡喃[3,2-a]咔唑-5-基）-N-（（1-（2-氯苯甲基）哌啶-4-基）甲基）丙烯酰胺（6bd）对OGD/R（氧-葡萄糖剥夺/再氧化）表现出比Claulansine F更好的神经保护作用。此外，6bd在体外可以穿越血脑屏障。更重要的是，与雷达伏酮相比，6bd具有更强的自由基清除活性。分子对接研究揭示了6bd可以与AChE的催化活性位点相互作用。所有这些出色的体外结果表明6bd作为一个值得进一步研究的领先结构。
• N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer’s agents
  作者：Urban Košak、Damijan Knez、Nicolas Coquelle、Boris Brus、Anja Pišlar、Florian Nachon、Xavier Brazzolotto、Janko Kos、Jacques-Philippe Colletier、Stanislav Gobec

  DOI：10.1016/j.bmc.2016.11.032

  日期：2017.1

  Alzheimer’s disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased. While BChE is a viable therapeutic target for alleviation of symptoms caused by cholinergic hypofunction, MAO-B is a potential therapeutic target for prevention of neurodegeneration in Alzheimer’s disease. Starting with piperidine-based selective human (h)BChE inhibitors and propargylamine-based

  在阿尔茨海默氏病患者的大脑中，丁酰胆碱酯酶（BChE）和单胺氧化酶B（MAO-B）的酶活性增加。虽然BChE是减轻胆碱能功能减退引起的症状的可行治疗靶标，但MAO-B是预防阿尔茨海默氏病神经退行性变的潜在治疗靶标。从基于哌啶的选择性人（h）BChE抑制剂和基于炔丙基胺的MAO抑制剂开始，我们已经设计，合成和生化评估了一系列N-炔丙基哌啶。所有这些化合物对hBChE的抑制作用均优于相关酶，乙酰胆碱酯酶，并在平行的人工膜渗透测定中越过血脑屏障。一种抑制剂（化合物的晶体结构）3）与hBChE复合显示其结合模式。三种化合物（4，5，6）表明MAO-B的伴随抑制。另外，最有效的hBChE抑制剂7和双重BChE和MAO-B抑制剂6是无细胞毒性的，并且受毒性淀粉样β肽物质保护的神经元SH-SY5Y细胞。